MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O.MK-2206 dihydrochloride (CAS 1032350-13-2) inc structure diagram It acts as an allosteric AKT inhibitor.MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Hirai et al. 2010
It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.
It is intended to be used with other cancer therapies that advanced tumours may become resistant to. __TOC__ Clinical trials 2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated. 2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.A trial of MK-2206 with chemotherapy or erlotinib for advanced cancer 2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials.Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. June 2016 31 phase II clinical trials are registered, many completed.MK-2206 phase=2 trials e.g. in colorectal cancer, breast cancer, and many others.
MK-2206 and COVID-19 Data shown in a study preprint suggest that SARS-CoV-2 infection decreases cellular autophagy and that MK-2206, which induces autophagy, reduced virus replication by up to 88% in vitro. The study's authors propose that MK-2206 should be tested in clinical trials as a potential treatment for COVID-19.
References